Harwood Feffer LLP Announces Investigation of Cubist Pharmaceuticals Inc.

NEW YORK, Dec. 8, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Cubist Pharmaceuticals Inc. ("Cubist" or the "Company") CBST concerning the proposed acquisition of the Company by Merck & Co., Inc. ("Merck").      

Under the terms of the transaction, Merck would purchase Cubist in a transaction valued at approximately $8.4 billion.  Cubist shareholders would receive $102.00 cash for each share of Cubist owned. 

Our investigation concerns whether the Cubist board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders. 

If you own Cubist shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Benjamin I. Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Craig Lowther
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com 
Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-cubist-pharmaceuticals-inc-300006472.html

SOURCE Harwood Feffer LLP